Details for New Drug Application (NDA): 215939
✉ Email this page to a colleague
NDA 215939 describes OXCARBAZEPINE, which is a drug marketed by Alkem Labs Ltd, Amneal Pharms, Aucta, Biocon Pharma, Bionpharma, Chartwell Rx, Hetero Labs Ltd Iii, Hikma, Kanchan Hlthcare, Macleods Pharms Ltd, Pai Holdings, Rubicon Research, Sun Pharm Inds Ltd, Ajanta Pharma Ltd, Apotex, Aurobindo Pharma Ltd, Riconpharma Llc, Ani Pharms, Annora Pharma, Breckenridge Pharm, Glenmark Pharms Ltd, Jubilant Cadista, Sun Pharm Inds, Taro, and Zydus, and is included in twenty-eight NDAs. It is available from thirty-nine suppliers. Additional details are available on the OXCARBAZEPINE profile page.
The generic ingredient in OXCARBAZEPINE is oxcarbazepine. There are twenty-one drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.
The generic ingredient in OXCARBAZEPINE is oxcarbazepine. There are twenty-one drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.
Summary for 215939
| Tradename: | OXCARBAZEPINE |
| Applicant: | Annora Pharma |
| Ingredient: | oxcarbazepine |
| Patents: | 0 |
Pharmacology for NDA: 215939
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 215939
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| OXCARBAZEPINE | oxcarbazepine | TABLET;ORAL | 215939 | ANDA | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8447 | 0615-8447-39 | 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8447-39) |
| OXCARBAZEPINE | oxcarbazepine | TABLET;ORAL | 215939 | ANDA | NCS HealthCare of KY, LLC dba Vangard Labs | 0615-8448 | 0615-8448-39 | 30 TABLET, FILM COATED in 1 BLISTER PACK (0615-8448-39) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Jan 11, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
| Approval Date: | Jan 11, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG | ||||
| Approval Date: | Jan 11, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
